Prospective Comparison of Low-Fluence Photodynamic Therapy Combined with Intravitreal Bevacizumab versus Bevacizumab Monotherapy for Choroidal Neovascularization in Age-Related Macular Degeneration

References

• Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375–413
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007;26:437–451
   PubMedGoogle Scholar
• Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116:S1–S7
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859–870
   PubMed Web of Science ®Google Scholar
• Klein RM, Klein RB. Avastin versus Lucentis: Ethical issues in treatment of age-related macular degeneration. Retina 2007;27:1163–1165
   PubMedGoogle Scholar
• Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections. Retina 2009;29:313–318
   PubMed Web of Science ®Google Scholar
• Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: Incidence, features, risk factors, and outcomes. Eye (Lond) 2012;26:1517–1526
   PubMed Web of Science ®Google Scholar
• Stewart MW. Endophthalmitis after injections of anti-vascular endothelial growth factor drugs. Retina 2011;31:1981–1982
   PubMedGoogle Scholar
• Inoue M, Kobayakawa S, Sotozono C, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica 2011;226:145–150
   PubMedGoogle Scholar
• Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth antagonists. Retina 2011;31:662–668
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Ophthalmology 2012;119:1001–1010
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Patra S, DaCosta J, et al. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. Ophthalmologica 2011;225:200–206
   PubMedGoogle Scholar
• Singh CN, Saperstein DA. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008;28:789–793
   PubMed Web of Science ®Google Scholar
• Smith BT, Dhalla MS, Shah GK, et al. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008;28:675–681
   PubMedGoogle Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin: one year results of 2 randomized clinical trials--TAP report. Arch Ophthalmol 1999;117:1329--1345
   Google Scholar
• Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 Am J Ophthalmol 2003;136:407–418
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372
   PubMed Web of Science ®Google Scholar
• Carneiro AM, Barthelmes D, Falcao MS, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011;225:211–221
   PubMed Web of Science ®Google Scholar
• Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988–993
   PubMed Web of Science ®Google Scholar
• Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IbeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273–1280
   PubMed Web of Science ®Google Scholar
• Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246:17–25
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Eur J Ophthalmol 2008;18:297–300
   PubMed Web of Science ®Google Scholar
• Boyer DS, Garcia R, Hao Y, et al; Registry of Visudyne AMD Therapy Writing Committee. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747–755
   PubMedGoogle Scholar
• Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179–1185
   PubMed Web of Science ®Google Scholar
• Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:180–184
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473–4480
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835–844
   PubMedGoogle Scholar